Anixa Biosciences, Inc. is a clinical stage biotechnology company focused on the treatment and prevention of cancer.
Therapeutics
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
Vaccines
We are developing a revolutionary vaccine technology focused on treating and preventing multiple forms of breast cancer.
Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine against ovarian cancer.
Lung, Colon, & Prostate Cancer Vaccines
We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Latest News & Events
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Read More...Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Read More...Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th
Read More...